On April 6, 2023 Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) reported that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel’s Board of Directors and granted as an inducement material to employees’ entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4) (Press release, Rigel, APR 6, 2023, View Source [SID1234629868]). Specifically, Rigel granted 108,600 stock options to three non-executive employees vesting over four years with a one-year cliff.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).